drugset / Trial / NCT05121402

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

NCT05121402

Phase 2 Withdrawn TLL Pharmaceutical, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to investigate the safety and efficacy of TLL018 compared with placebo in subjects with moderate to severe ulcerative colitis.

Timeline

Start
2022-12-30
Primary completion
2023-07-01
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TLL018 Unknown

Indications